gemcitabine has been researched along with Hyperglycemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelrahman, L; Banerjee, S; Kesh, K; Mendez, R | 1 |
| He, J; Jia, B; Yan, J; Yang, J | 1 |
| Aoki, H; Hisada, T; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Shimizu, Y; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
1 trial(s) available for gemcitabine and Hyperglycemia
| Article | Year |
|---|---|
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Hyperglycemia; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome | 2008 |
2 other study(ies) available for gemcitabine and Hyperglycemia
| Article | Year |
|---|---|
Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma.
Topics: Animals; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Dysbiosis; Gastrointestinal Microbiome; Gemcitabine; Hyperglycemia; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Pancreatic Neoplasms | 2020 |
Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Blood Glucose; China; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Hyperglycemia; Incidence; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Registries; Sorafenib | 2017 |